<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Diabetes Mellitus Reference</title>
<style>
  body { font-family: Arial, sans-serif; margin: 20px; background-color: #f9f9f9; color: #333; }
  .container { max-width: 1000px; margin: auto; background: #fff; padding: 20px; border-radius: 8px; box-shadow: 0 0 8px rgba(0,0,0,0.1); }
  h1, h2 { text-align: center; color: #0077aa; }
  summary { font-weight: bold; cursor: pointer; }
  details { margin: 10px 0; }
  .section { margin: 20px 0; }
</style>
</head>
<body>
<div class="container">
  <h1>Diabetes Mellitus</h1>
  <p>This reference summarizes diabetes mellitus in a concise format, with the option to expand for full details where needed.</p>

  <div class="section">
    <h2>Summary</h2>
    <p>Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia due to defects in insulin secretion, insulin action, or both. There are two major types: Type 1 (autoimmune Œ≤-cell destruction ‚Üí absolute insulin deficiency) and Type 2 (insulin resistance + relative insulin deficiency). Goals of treatment include glycemic control, prevention of micro- and macrovascular complications, and lifestyle modification.</p>
  </div>

  <div class="section">
    <h2>Details by Section</h2>

    <details>
      <summary>‚öôÔ∏è Types & Pathophysiology</summary>
      <p><b>Type 1 DM:</b> Autoimmune destruction of Œ≤-cells (HLA-DR3/DR4) ‚Üí absolute insulin deficiency. Onset in childhood or adolescence. High risk of DKA.</p>
      <p><b>Type 2 DM:</b> Insulin resistance + progressive Œ≤-cell dysfunction. Associated with obesity and sedentary lifestyle. Onset in adulthood.</p>
      <p>Other types: MODY, gestational diabetes, pancreatogenic diabetes, drug-induced.</p>
    </details>

    <details>
      <summary>üìä Diagnosis</summary>
      <p>Diagnostic criteria (any of the following):</p>
      <ul>
        <li>FPG ‚â• 126 mg/dL</li>
        <li>2h OGTT ‚â• 200 mg/dL</li>
        <li>HbA1c ‚â• 6.5%</li>
        <li>Random glucose ‚â• 200 mg/dL + symptoms</li>
      </ul>
      <p>Screen high-risk patients periodically.</p>
    </details>

    <details>
      <summary>ü©∫ Clinical Features</summary>
      <p>Polyuria, polydipsia, polyphagia, unexplained weight loss (more common in Type 1), fatigue, recurrent infections. In Type 2, often asymptomatic for years.</p>
    </details>

    <details>
      <summary>üíä Management</summary>
      <p><b>Type 1:</b> Insulin therapy, lifestyle modification, monitoring.</p>
      <p><b>Type 2:</b> Lifestyle modification + metformin first-line; add GLP-1 RA, SGLT2i, insulin as needed. Control BP, lipids, and screen for complications.</p>
    </details>

    <details>
      <summary>üî¨ Complications</summary>
      <p><b>Microvascular:</b> Retinopathy, nephropathy, neuropathy.</p>
      <p><b>Macrovascular:</b> CAD, stroke, PAD.</p>
      <p><b>Acute:</b> DKA, HHS, hypoglycemia.</p>
    </details>

    <details>
      <summary>üìö Special Considerations</summary>
      <p>Diabetes in pregnancy, in children, and management of comorbidities (e.g., obesity, depression) require tailored approaches.</p>
    </details>
  </div>

  <p style="text-align: center; font-size: 0.9em; color: #666;">Based on ADA Standards of Care 2025 and Amboss Clinical Guidelines.</p>
</div>
</body>
</html>